What's new in topical treatments for psoriasis

The efficacy and safety of interleukin-17 and interleukin-23 inhibitors in psoriatic arthritis across multiple disease domains.

Dermatology online journal·2026

Brodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence.

Journal of drugs in dermatology : JDD·2026

More Than Skin Clearance: Connecting Brodalumab's Mechanism of Action to Patient Outcomes in Psoriasis.

Journal of drugs in dermatology : JDD·2025

IL-17C as a Driver of Inflammation in Psoriasis.

Advances in therapy·2025

Brodalumab as a Second-Line Therapy in Psoriasis: Rapid Response and Unique Mechanism of Action After Biologic Failure.

Dermatology and therapy·2025

Highly Pathogenic Avian Influenza A(H5N1) Virus Infection in a Child with No Known Exposure - San Francisco, California, December 2024-January 2025.

MMWR. Morbidity and mortality weekly report·2025

Association Between Hidradenitis Suppurativa and Polycystic Ovary Syndrome.

Cutis·2026

Medical Decision-Making in Evaluation and Management Coding: Practical Applications and Key Clarifications.

Cutis·2026

Using Intralesional Adalimumab for Chronic Refractory Cutaneous Granulomatous Inflammation.

Cutis·2026

Getting a Grip on Occupational Hand Dermatitis: Key Considerations for Evaluation and Management.

Cutis·2026

Horse Flies: Identification, Bite Reactions, and Clinical Management.

Cutis·2026

Pembrolizumab-Induced Bullous Pemphigoid: Navigating Diagnostic Challenges and Treatment Resistance.

Cutis·2026

Enabling equitable open access to commercially funded research publications.

PLoS medicine·2026

Buprenorphine Dispensed by Pharmacies and Administered in Emergency Departments in Urban and Rural Areas - United States, 2019-2025.

MMWR. Morbidity and mortality weekly report·2026

Rheumatoid Arthritis Guidelines Require Dietary Recommendations: An Overlooked Opportunity.

Clinical nutrition ESPEN·2026

Assessment of the impact of valproic acid co-administration on clozapine plasma concentrations in Tunisian patients.

Drug metabolism and personalized therapy·2026

Benefit-Risk of Voxelotor, Crizanlizumab, and L-Glutamine in Sickle Cell Disease: A Systematic Review.

The American journal of the medical sciences·2026

Cross-national disparities in drug interaction reporting and assessment between Switzerland and Austria: A retrospective, registry-based study using pharmacovigilance data.

PloS one·2026

Related Experiment Videos

What's new in topical treatments for psoriasis

Related Concept Videos

The efficacy and safety of interleukin-17 and interleukin-23 inhibitors in psoriatic arthritis across multiple disease domains.

Brodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence.

More Than Skin Clearance: Connecting Brodalumab's Mechanism of Action to Patient Outcomes in Psoriasis.

IL-17C as a Driver of Inflammation in Psoriasis.

Brodalumab as a Second-Line Therapy in Psoriasis: Rapid Response and Unique Mechanism of Action After Biologic Failure.

Highly Pathogenic Avian Influenza A(H5N1) Virus Infection in a Child with No Known Exposure - San Francisco, California, December 2024-January 2025.

Association Between Hidradenitis Suppurativa and Polycystic Ovary Syndrome.

Medical Decision-Making in Evaluation and Management Coding: Practical Applications and Key Clarifications.

Using Intralesional Adalimumab for Chronic Refractory Cutaneous Granulomatous Inflammation.

Getting a Grip on Occupational Hand Dermatitis: Key Considerations for Evaluation and Management.

Horse Flies: Identification, Bite Reactions, and Clinical Management.

Pembrolizumab-Induced Bullous Pemphigoid: Navigating Diagnostic Challenges and Treatment Resistance.

Enabling equitable open access to commercially funded research publications.

Buprenorphine Dispensed by Pharmacies and Administered in Emergency Departments in Urban and Rural Areas - United States, 2019-2025.

Rheumatoid Arthritis Guidelines Require Dietary Recommendations: An Overlooked Opportunity.

Assessment of the impact of valproic acid co-administration on clozapine plasma concentrations in Tunisian patients.

Benefit-Risk of Voxelotor, Crizanlizumab, and L-Glutamine in Sickle Cell Disease: A Systematic Review.

Cross-national disparities in drug interaction reporting and assessment between Switzerland and Austria: A retrospective, registry-based study using pharmacovigilance data.

Related Experiment Videos

What's new in topical treatments for psoriasis

Related Concept Videos

Related Articles